Yes—absolutely.
In fact, regulatory strategy is most powerful before a physical prototype exists.
At the earliest stage, regulatory thinking acts as a design compass. It tells you what you can build, how risky it will be, and what proof you’ll eventually need—before you spend real money on engineering.
How Regulatory Strategy Works at the “Paper Stage”
Even without a prototype, regulatory strategy can shape three critical pillars of development.
1. Defining Design Inputs Before Design Begins
Regulatory strategy helps translate a raw idea into regulatory-ready design inputs, including:
Intended use and indications for use
User population and use environment
Safety-critical functions
Performance expectations tied to risk
These inputs form the foundation of FDA design controls. When they are defined early, engineering efforts stay aligned with regulatory expectations instead of drifting into redesign territory.
From the perspective of the U.S. Food and Drug Administration, design controls are not optional—they are the backbone of device development.
2. Early Risk Classification Without Hardware
You do not need a prototype to perform meaningful risk analysis.
Using concept-level information, regulatory strategy can:
Estimate device classification (Class I, II, or III)
Identify primary hazards (biological, electrical, software, usability)
Anticipate testing categories such as biocompatibility, software validation, or human factors
This early risk framing prevents teams from unknowingly designing a high-risk device when a lower-risk approach would meet the same clinical need.
3. Evidence Planning Before Testing Exists
One of the biggest advantages of early regulatory strategy is evidence planning without waste.
At the paper stage, teams can:
Map risks to required bench, animal, or clinical evidence
Identify which standards and guidances will apply
Decide what data must be generated—and what can be avoided
This allows development programs to be built intentionally, not reactively.
Once testing starts, it is already too late to ask whether the data will count.
Why This Saves Time and Money
Early regulatory strategy:
Prevents unnecessary prototyping
Reduces the chance of forced regulatory pathway changes
Ensures early capital is spent on work that survives FDA review
For early-stage companies, this can mean the difference between reaching a regulatory milestone—or running out of runway.
Where Kandih Comes In
This is where Kandih Group adds the most value.
Kandih supports founders at the paper stage, before engineering costs escalate, by:
Pressure-testing ideas against FDA logic
Defining regulatory-ready intended use and design inputs
Conducting concept-level risk assessments
Outlining evidence strategies aligned with FDA expectations
Helping teams deploy capital efficiently and defensibly
Instead of guessing what FDA will want later, founders can design forward with confidence.
Bottom Line
You don’t need a prototype to start regulatory strategy.
You need regulatory strategy to know what prototype to build.
Starting early de-risks development, protects capital, and accelerates time to market.
That’s how Kandih helps innovators move faster—without breaking things later.
References
FDA – Design Controls for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/design-controls-medical-devices
FDA – Classify Your Medical Device
https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
FDA – ISO 14971: Risk Management for Medical Devices
https://www.fda.gov/medical-devices/standards-and-conformity-assessment-program/recognized-consensus-standards
FDA – Benefit-Risk Factors for Medical Devices
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/factors-consider-when-making-benefit-risk-determinations-medical-device